Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer.

Watanabe D, Fujii H, Matsuhashi N, Iihara H, Yamada Y, Ishihara T, Takahashi T, Yoshida K, Suzuki A.

Anticancer Res. 2020 Apr;40(4):2379-2386. doi: 10.21873/anticanres.14207.

PMID:
32234941
2.

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K.

Oncologist. 2020 Mar;25(3):e469-e476. doi: 10.1634/theoncologist.2019-0541. Epub 2019 Nov 20.

3.

Effect of preservation on the physical and chemical properties of the temporal fascia.

Tarumoto S, Sugahara K, Hashimoto M, Hirose Y, Tsuda J, Takemoto Y, Fujii H, Matsuura T, Shimogori H, Ohgi J, Yamashita H.

Auris Nasus Larynx. 2020 Jan 23. pii: S0385-8146(19)30936-8. doi: 10.1016/j.anl.2019.12.004. [Epub ahead of print]

PMID:
31983479
4.

Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin.

Watanabe D, Fujii H, Yamada Y, Iihara H, Ishihara T, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A.

Anticancer Res. 2020 Jan;40(1):299-304. doi: 10.21873/anticanres.13953.

PMID:
31892580
5.

Implementation of a standardised pharmacist check of medical orders prior to preparation of anticancer drugs to reduce drug wastage.

Yamada H, Kobayashi R, Shimizu S, Yamada Y, Ishida M, Shimoda H, Kato-Hayashi H, Fujii H, Iihara H, Tanaka H, Suzuki A.

Int J Clin Pract. 2020 Apr;74(4):e13464. doi: 10.1111/ijcp.13464. Epub 2019 Dec 19.

PMID:
31830345
6.

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K.

Oncologist. 2019 Nov 20. pii: theoncologist.2019-0541. doi: 10.1634/theoncologist.2019-0541. [Epub ahead of print]

7.

Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma.

Yamada Y, Ohno Y, Kato Y, Kobayashi R, Hayashi H, Miyahara S, Nakane K, Mizutani K, Yokoi S, Fujii H, Iihara H, Ishihara T, Deguchi T, Sugiyama T, Suzuki A.

Cancer Chemother Pharmacol. 2019 Nov;84(5):987-992. doi: 10.1007/s00280-019-03935-x. Epub 2019 Sep 3.

PMID:
31482225
8.

Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.

Matsuhashi N, Takahashi T, Fujii H, Suetsugu T, Fukada M, Iwata Y, Tokumaru Y, Imai T, Mori R, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Futamura M, Yoshida K.

Mol Clin Oncol. 2019 Oct;11(4):390-396. doi: 10.3892/mco.2019.1899. Epub 2019 Jul 18.

9.

High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.

Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A.

Med Oncol. 2019 Jun 3;36(7):63. doi: 10.1007/s12032-019-1288-7.

PMID:
31161433
10.

Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome.

Iihara H, Fujii H, Yoshimi C, Kobayashi R, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A.

Cancer Chemother Pharmacol. 2019 Mar;83(3):393-398. doi: 10.1007/s00280-018-3736-z. Epub 2018 Dec 18.

11.

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy.

Yamada Y, Fujii H, Watanabe D, Kato-Hayashi H, Ohata K, Kobayashi R, Ishihara T, Uemura S, Iwashita T, Shimizu M, Suzuki A.

Cancers (Basel). 2018 Nov 16;10(11). pii: E454. doi: 10.3390/cancers10110454.

12.

Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy.

Fujii H, Hirose C, Ishihara M, Iihara H, Imai H, Tanaka Y, Matsuhashi N, Takahashi T, Yamaguchi K, Yoshida K, Suzuki A.

Anticancer Res. 2018 Nov;38(11):6367-6373. doi: 10.21873/anticanres.12995.

PMID:
30396959
13.

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.

Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A.

Cancer Chemother Pharmacol. 2019 Jan;83(1):123-129. doi: 10.1007/s00280-018-3711-8. Epub 2018 Oct 30.

14.

Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.

Fujii H, Iihara H, Kajikawa N, Kobayashi R, Suzuki A, Tanaka Y, Yamaguchi K, Yoshida K, Itoh Y.

Anticancer Res. 2017 Dec;37(12):6831-6837.

PMID:
29187462
15.

Oral administration of geranylgeranylacetone to protect vestibular hair cells.

Nagato S, Sugahara K, Hirose Y, Takemoto Y, Hashimoto M, Fujii H, Yamashita H.

Auris Nasus Larynx. 2018 Jun;45(3):412-416. doi: 10.1016/j.anl.2017.07.006. Epub 2017 Aug 7.

PMID:
28781154
16.

Distinct Distribution of Immunocytes in a Retropharyngeal Lymphadenopathy Associated with Kawasaki Disease: A Case Study Compared with Tonsillitis.

Okada S, Kobayashi-Fujiwara Y, Oga A, Furuta T, Ikemoto K, Fujii H, Sakata Y, Suzuki Y, Hasegawa S, Kusuda T, Itoh H, Yamashita H, Ohga S.

Cardiology. 2017;137(4):237-243. doi: 10.1159/000467388. Epub 2017 May 4.

PMID:
28467980
17.

Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk.

Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K, Itoh Y.

Anticancer Res. 2016 Dec;36(12):6527-6533.

PMID:
27919978
18.

Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.

Fujii H, Iihara H, Suzuki A, Kobayashi R, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1209-15. doi: 10.1007/s00280-016-3039-1. Epub 2016 Apr 22.

PMID:
27106835
19.

[Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].

Fujii H, Iihara H, Ishihara M, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y.

Gan To Kagaku Ryoho. 2016 Feb;43(2):229-33. Japanese.

PMID:
27067688
20.

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens.

Iihara H, Ishihara M, Fujii H, Yoshimi C, Yamada M, Suzuki A, Yamaguchi K, Futamura M, Yoshida K, Itoh Y.

J Cancer. 2016 Mar 18;7(5):569-75. doi: 10.7150/jca.13637. eCollection 2016.

Supplemental Content

Loading ...
Support Center